v3.26.1
Collaboration and License Agreements - Astellas Pharma Inc - Additional Information (Details)
$ in Thousands
1 Months Ended 3 Months Ended
Mar. 23, 2020
USD ($)
Target
Jan. 31, 2023
USD ($)
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Deferred revenue         $ 28,467 $ 94,063 $ 212,315
Astellas Pharma Inc.              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Deferred revenue         8,600    
Collaboration and License Agreement | Astellas Pharma Inc.              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Number of targets selected | Target 1            
Number of additional collaboration target | Target 3            
Upfront payment received $ 80,000            
Total transaction price 103,200            
Research and development service fees $ 23,200            
Milestone payments received   $ 5,000 $ 5,000 $ 5,000      
Additional milestone payment received     $ 5,000 $ 5,000      
Deferred revenue         8,600 17,400  
Amount due from customer         $ 900 $ 1,100  
Collaboration and License Agreement | Astellas Pharma Inc. | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Number of targets | Target 4            
Right to expand the number of additional collaboration target | Target 5            
Contingent milestone payments receivable $ 1,200,000            
Collaboration and License Agreement | Astellas Pharma Inc. | Minimum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Right to expand the number of additional collaboration target | Target 3